Persistent microscopic active inflammatory lesions in the central nervous system of a patient with neuromyelitis optica treated with oral prednisolone for more than 40 years

Lennon, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016/S0140-6736(04)17551-X Wingerchuk, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212/01.wnl.0000216139.44259.74 Wingerchuk, 1999, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, 53, 1107, 10.1212/WNL.53.5.1107 Kitley, 2012, Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan, Brain, 135, 1834, 10.1093/brain/aws109 Lucchinetti, 2002, A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica, Brain, 125, 1450, 10.1093/brain/awf151 Misu, 2007, Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis, Brain, 130, 1224, 10.1093/brain/awm047 Papadopoulos, 2014, Treatment of neuromyelitis optica: state-of-the-art and emerging therapies, Nat Rev Neurol, 10, 493, 10.1038/nrneurol.2014.141 Watanabe, 2007, Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis, Mult Scler, 13, 968, 10.1177/1352458507077189